Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Expert Systems Celebrates Milestone in Clinical Development of Lonitoclax BCL-2 Inhibitor
Details : Lonitoclax has a best-in-class potency and selectivity against BCL-2. Currently, it is being evaluated for the treatment of chronic lymphocytic leukemia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 17, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Eilean Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Expert Systems Expands Partnership with Eilean Therapeutics for PTPN2 Inhibitor Program
Details : The partnership aims to support the clinical advancement of Eilean's lead PTPN2 inhibitor, which is being evaluated in the preclinical trial studies for the treatment of patients related to neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Eilean Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Polku Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Expert Systems Expands European Operations For Neurodegenerative Drug Discovery
Details : The collaboration of Polku Therapeutics with Expert Systems to focus on the early-stage drug discovery for the treatment of neurodegenerative disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Polku Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration